Illumina, Inc., a major developer of next-generation sequencing and genomic technologies, has completed its acquisition of SomaLogic, a company known for its advanced data-driven proteomics platforms. The transaction, finalized on January 30, 2026, marks a significant expansion of Illumina’s multiomics portfolio by incorporating high-throughput protein analysis alongside its established genomic offerings. 
The addition of SomaLogic’s technology enhances Illumina’s ability to deliver scalable and flexible solutions for large-scale biological research and drug discovery. Integrating SomaLogic’s proteomic assays with Illumina’s existing sequencing ecosystem, computational tools and multiomics infrastructure is expected to enable researchers to generate richer datasets connecting protein dynamics with genomic information. 
SomaLogic’s platforms are designed to offer deep biological insight into protein functions, interactions, and molecular changes, expanding the analytical scope available to life science investigators. Combined with Illumina’s sequencing instruments, software such as DRAGEN, and cloud-based multiomics analytics, the expanded portfolio aims to support large research programs requiring comprehensive views of complex biological systems. 
The acquisition reinforces Illumina’s strategic direction toward broad multiomic solutions that bring genomics and proteomics closer together, increasing the breadth of scientific insight that can be achieved from a single sample. It also positions the company for growth in the expanding market for proteomics technologies, an area of rising interest in pharmaceutical research and clinical science. 
The transaction terms include a base purchase price of $350 million in cash from Illumina, with additional contingent payments of up to $75 million tied to performance milestones and royalties. Funding for the acquisition was sourced from Illumina’s cash reserves. Financial details, including the impact on Illumina’s upcoming financial reporting, were noted to be discussed during the company’s earnings call scheduled for February 5, 2026. 
Illumina’s relationship with SomaLogic dates back to a 2021 partnership focused on integrating SomaLogic’s proteomic assays with Illumina’s high- throughput sequencing systems. The acquisition builds on this collaboration, providing continuity for existing customers and support for service providers that employ SomaLogic’s technologies. 
The combined capabilities are expected to benefit researchers and organizations seeking to deepen scientific understanding and accelerate discoveries across health and disease research, drug development, and systems biology.
Also Read